{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:41:29Z","timestamp":1759452089252,"version":"build-2065373602"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.semnephrol.2021.03.003","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T16:09:16Z","timestamp":1623686956000},"page":"85-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease"],"prefix":"10.1016","volume":"41","author":[{"given":"Robert C.","family":"Stanton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"United States Renal Data System 2019 annual data report: epidemiology of kidney disease in the United States","key":"10.1016\/j.semnephrol.2021.03.003_bib0001"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2019.08.033","article-title":"Should the definition of CKD be changed to include age-adapted GFR criteria?","volume":"97","author":"Glassock","year":"2020","journal-title":"YES. Kidney Int."},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0003","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.kint.2019.08.032","article-title":"Should the definition of CKD be changed to include age-adapted GFR criteria?\": Con: the evaluation and management of CKD, not the definition, should be age-adapted","volume":"97","author":"Levey","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0004","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2215\/CJN.11511114","article-title":"Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view","volume":"10","author":"Lambers Heerspink","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0006","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2215\/CJN.01610215","article-title":"Rebuttal of the pro view: albuminuria is an appropriate therapeutic target in patients with CKD","volume":"10","author":"Fried","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0007","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.10681014","article-title":"Albuminuria is not an appropriate therapeutic target in patients with CKD: the con view","volume":"10","author":"Fried","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0008","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2215\/CJN.02760315","article-title":"Rebuttal of the con view: albuminuria is an appropriate therapeutic target in patients with CKD","volume":"10","author":"Lambers Heerspink","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0009","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0010","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1161\/CIRCULATIONAHA.107.723270","article-title":"Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0011","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1681\/ASN.2005121288","article-title":"Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms","volume":"17","author":"Stehouwer","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0012","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2215\/CJN.03190906","article-title":"Microalbuminuria and cardiovascular disease","volume":"2","author":"Weir","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0013","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0014","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.HYP.0000154082.72286.2a","article-title":"Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study","volume":"45","author":"Ibsen","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1053\/j.ajkd.2011.12.009","article-title":"Longitudinal progression trajectory of GFR among patients with CKD","volume":"59","author":"Li","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0016","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc16-0950","article-title":"Patterns of estimated glomerular filtration rate decline leading to end-stage renal disease in type 1 diabetes","volume":"39","author":"Skupien","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.ajkd.2017.08.010","article-title":"Longitudinal estimated GFR trajectories in patients with and without type 2 diabetes and nephropathy","volume":"71","author":"Weldegiorgis","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0018","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.semnephrol.2021.03.003_bib0019","first-page":"S4","article-title":"Summary of revisions: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0020","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0021","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0022","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0023","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0024","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","article-title":"Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial","volume":"141","author":"Cannon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose co-transporters and their inhibition: clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0026","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/1574886313666180226103408","article-title":"Risks associated with SGLT2 inhibitors: an overview","volume":"13","author":"Singh","year":"2018","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0027","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0028","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.semnephrol.2021.03.003_bib0029a","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0029","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0030","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0031","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.113.007071","article-title":"Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?","volume":"129","author":"Stanton","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0032","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0033","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0034","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0035","doi-asserted-by":"crossref","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na(+)\/H(+) exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0036","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target","volume":"5","author":"Santer","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 3","key":"10.1016\/j.semnephrol.2021.03.003_bib0037","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1097\/01.ASN.0000077413.41276.17","article-title":"Role of advanced glycation end products in diabetic nephropathy","volume":"14","author":"Forbes","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"10.1016\/j.semnephrol.2021.03.003_bib0038","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/j.dsx.2015.10.004","article-title":"Measurement of urinary advanced glycation end-products (AGEs) using a fluorescence assay for metabolic syndrome-related screening tests","volume":"10","author":"Suehiro","year":"2016","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0039","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1681\/ASN.2018080844","article-title":"Macula densa SGLT1-NOS1-tubuloglomerular feedback pathway, a new mechanism for glomerular hyperfiltration during hyperglycemia","volume":"30","author":"Zhang","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2337\/db16-0607","article-title":"Renal and systemic effects of calorie restriction in patients with type 2 diabetes with abdominal obesity: a randomized controlled trial","volume":"66","author":"Ruggenenti","year":"2017","journal-title":"Diabetes."},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0041","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dbi16-0056","article-title":"Back to the future: glomerular hyperfiltration and the diabetic kidney","volume":"66","author":"Tuttle","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0042","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1681\/ASN.2013090950","article-title":"The proximal tubule and albuminuria: really!","volume":"25","author":"Dickson","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0043","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0044","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/CS-2019-0472","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0046","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0047","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0048","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0049","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0050","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/ki.2014.236","article-title":"The potential for renoprotection with incretin-based drugs","volume":"86","author":"Tanaka","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0051","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fendo.2019.00080","article-title":"Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes","volume":"10","author":"Deacon","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0052","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/dom.13041","article-title":"Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial","volume":"19","author":"Groop","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0053","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0054","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0055","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","volume":"7","author":"Pollock","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0056","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3803\/EnM.2019.34.1.80","article-title":"Effects of dipeptidyl peptidase-4 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"34","author":"Bae","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0057","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MNH.0000000000000185","article-title":"Endothelin-1 and the kidney: new perspectives and recent findings","volume":"25","author":"De Miguel","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0058","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0059","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0060","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1093\/ndt\/gft029","article-title":"Uric acid and chronic kidney disease: which is chasing which?","volume":"28","author":"Johnson","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0061","doi-asserted-by":"crossref","first-page":"54","DOI":"10.15420\/ecr.2016:4:2","article-title":"Uric acid and cardiovascular disease: an update","volume":"11","author":"Muiesan","year":"2016","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0062","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0063","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0064","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0065","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2215\/CJN.01410210","article-title":"Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome","volume":"5","author":"Schrier","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0066","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0067","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0068","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0069","doi-asserted-by":"crossref","first-page":"e0254","DOI":"10.1097\/MD.0000000000010254","article-title":"The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis","volume":"97","author":"Pei","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0070","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0071","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2215\/CJN.12651018","article-title":"Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study","volume":"14","author":"Spinowitz","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0072","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0073","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-151-1-200907070-00120","article-title":"Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials","volume":"151","author":"Bilous","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2021.03.003_bib0074","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929521000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929521000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:37:54Z","timestamp":1759448274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929521000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0270929521000334"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2021.03.003","relation":{},"ISSN":["0270-9295"],"issn-type":[{"type":"print","value":"0270-9295"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2021.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}